TrialHaematologica2015

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.

Nicolas Boissel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.